Pharma Co. Misled Investors About Hepatitis Drug, Suit Says
Biopharmaceutical company Achillion Pharmaceuticals Inc. was hit Wednesday with a proposed class action accusing the company of failing to disclose that its hepatitis drug sovaprevir doesn't interact well with certain other...To view the full article, register now.
Already a subscriber? Click here to view full article